Rationale Synergistic or supra-additive interactions between the anorectics (dex)fenfluramine and phentermine have been reported previously in the rat and in the clinic. Studies with 5-HT2C antagonists and 5-HT2C knockouts have demonstrated dexfenfluramine hypophagia in the rodent to be mediated by actions at the 5-HT2C receptor. Given the recent FDA approv-al of the selective 5-HT2C agonist lorcaserin (BELVIQ®) for weight management, we investigated the interaction between phentermine and 5-HT2C agonists on food intake. Objectives This study aims to confirm dexfenfluramine-phentermine (dex-phen) synergy in a rat food intake assay, to extend these findings to other 5-HT2C agonists, and to determine whether pharmacokinetic interactions could...
The 5-HT2C receptor agonist, lorcaserin, and the 5-HT6 receptor antagonist, SB-742457, promote satie...
This study investigated the role of the 5-HT2/1C receptor antagonist ritanserin on d-fenfluramine (d...
Combined dopamine (DA) and 5‐hydroxytryptamine (5‐HT) releasers such as phentermine (PHEN) and fenfl...
International audienceThe now-banned anorectic molecule, dexfenfluramine, promotes serotonin release...
The now-banned anorectic molecule, dexfenfluramine, promotes serotonin release through a serotonin t...
Rationale The possible role of compensatory changes in 5-HT2C receptors in the reduced hypophagic ac...
RATIONALE: Whilst the FDA-approved anorectic, lorcaserin and various 5-hydroxytryptamine (5-HT)6 rec...
that c wha recep rs an preclinical literature (e.g., Blundell, 1984; Simansky, 2002). These include ...
The studies reported here examined the role of the 5-hydroxytryptamine (5-HT)(2C) receptor subtype i...
RATIONALE: The 5-HT transporter (5-HTT) is implicated in the regulation of appetite. Expression of t...
Serotonin has been implicated in the control of satiety for almost four decades. Historically, the i...
RATIONALE The monoamine reuptake inhibitor sibutramine reduces food intake but the receptor subtypes...
PURPOSE: To explore the interaction between antiobesity drug, topiramate, and hypolipidemic drug, at...
The effects of two indirect (dexfenfluramine and fluoxetine) and one direct (RU 24969) serotonergic ...
Obesity is a major risk factor in the development of conditions such as hypertension, hyperglycemia,...
The 5-HT2C receptor agonist, lorcaserin, and the 5-HT6 receptor antagonist, SB-742457, promote satie...
This study investigated the role of the 5-HT2/1C receptor antagonist ritanserin on d-fenfluramine (d...
Combined dopamine (DA) and 5‐hydroxytryptamine (5‐HT) releasers such as phentermine (PHEN) and fenfl...
International audienceThe now-banned anorectic molecule, dexfenfluramine, promotes serotonin release...
The now-banned anorectic molecule, dexfenfluramine, promotes serotonin release through a serotonin t...
Rationale The possible role of compensatory changes in 5-HT2C receptors in the reduced hypophagic ac...
RATIONALE: Whilst the FDA-approved anorectic, lorcaserin and various 5-hydroxytryptamine (5-HT)6 rec...
that c wha recep rs an preclinical literature (e.g., Blundell, 1984; Simansky, 2002). These include ...
The studies reported here examined the role of the 5-hydroxytryptamine (5-HT)(2C) receptor subtype i...
RATIONALE: The 5-HT transporter (5-HTT) is implicated in the regulation of appetite. Expression of t...
Serotonin has been implicated in the control of satiety for almost four decades. Historically, the i...
RATIONALE The monoamine reuptake inhibitor sibutramine reduces food intake but the receptor subtypes...
PURPOSE: To explore the interaction between antiobesity drug, topiramate, and hypolipidemic drug, at...
The effects of two indirect (dexfenfluramine and fluoxetine) and one direct (RU 24969) serotonergic ...
Obesity is a major risk factor in the development of conditions such as hypertension, hyperglycemia,...
The 5-HT2C receptor agonist, lorcaserin, and the 5-HT6 receptor antagonist, SB-742457, promote satie...
This study investigated the role of the 5-HT2/1C receptor antagonist ritanserin on d-fenfluramine (d...
Combined dopamine (DA) and 5‐hydroxytryptamine (5‐HT) releasers such as phentermine (PHEN) and fenfl...